Sickle Cell Disease Drugs Market (2026-2032)

Sickle Cell Disease Drugs Market: Wider Disease-Modifying Treatment, Persistent VOC Burden and Gene Therapy Reshape SCD Care

The Global Sickle Cell Disease Drugs Market was valued at approximately USD 1.15 billion in 2025 and is projected to reach USD 2.45 billion by 2032, expanding at a CAGR of approximately 11.4% during 2026–2032. North America accounted for an estimated USD 470 million in 2025, including approximately USD 440 million from the United States, reflecting higher diagnosis rates, use of branded therapies, stronger reimbursement and the early commercial uptake of gene therapy. Global disease-modifying treatment volume was approximately 1.3 million patient-years in 2025 and is expected to reach 2.0–2.1 million patient-years by 2032.

Sickle cell disease has a much larger epidemiological population than its current treated market suggests. WHO estimated that 7.74 million people were living with SCD globally in 2021, with approximately 515,000 affected births annually and nearly 80% of cases concentrated in sub-Saharan Africa. WHO also estimated approximately 376,000 deaths associated with SCD in 2021, highlighting a burden that extends beyond deaths formally recorded with SCD as the underlying cause.

The global prevalent population was estimated at approximately 8.2 million in 2025, while about 4.75 million patients were diagnosed or clinically identified. Approximately 3.7 million patients were considered broadly eligible for disease-modifying treatment, yet only about 1.32 million were receiving such therapy. The gap is particularly pronounced in countries carrying the largest disease burden, where newborn screening, hematology services, continuous drug availability and long-term follow-up remain inconsistent.

Recurrent Vaso-Occlusive Crises Define the Highest-Need Treatment Population

Vaso-occlusive crises remain the principal clinical event influencing treatment escalation. Repeated microvascular obstruction causes severe pain and contributes to acute chest syndrome, stroke, renal disease, chronic anemia and progressive organ damage. Approximately 1.4–1.7 million diagnosed patients globally were estimated to have moderate-to-severe disease or recurrent VOCs in 2025, making this group particularly important for newer disease-modifying and advanced treatments.

The burden rises sharply in patients requiring regular transfusion or experiencing repeated crises. A recent U.S. study of frequently transfused patients reported approximately 4.0 VOCs, 8.3 red-cell transfusions and 2.3 inpatient admissions per patient annually, with mean healthcare expenditure of approximately USD 106,123 per patient per year. Other real-world analyses of recurrent-VOC populations have reported approximately 5 VOCs, 2.7 inpatient admissions and 5 emergency-department visits annually, with healthcare costs approaching USD 67,282 per patient.

These patients represent a clinically important population for therapies capable of reducing VOC frequency, hospitalization and cumulative organ damage.

Hydroxyurea Remains the Largest Treatment Segment

Hydroxyurea remained the leading treatment segment by patient volume in 2025, accounting for approximately 1.15–1.20 million patient-years, or close to 90% of global disease-modifying treatment volume. Its ability to increase fetal hemoglobin and reduce sickling keeps it central to standard care despite the expansion of newer therapies.

Access remains uneven. SickleInAfrica registry data reported hydroxyurea utilization of approximately 21% in Ghana, 12% in Nigeria and 6% in Tanzania, illustrating how treatment penetration remains low in several high-burden markets.

Persistence also limits real-world effectiveness. One U.S. claims analysis reported a mean hydroxyurea medication-possession ratio of 0.52, while only 22.3% of patients achieved an MPR of at least 80% and 58.9% discontinued therapy within 12 months under the study definition.

Hydroxyurea therefore dominates treatment volume but leaves substantial clinical space for additional therapies among patients with inadequate VOC control, poor adherence, intolerance or progressive complications.

Higher-Value Branded Therapies Serve a Narrower Patient Pool

L-glutamine and crizanlizumab address considerably smaller patient populations but carry substantially higher treatment costs than generic hydroxyurea. Approximately 25,000–35,000 patients were estimated to receive L-glutamine in 2025, while around 15,000–20,000 patients received crizanlizumab-equivalent treatment.

Commercial performance has increasingly depended on competition and reimbursement rather than eligible population alone. Emmaus Life Sciences reported USD 12.45 million in net revenue during 2025, down 25% from 2024, following the entry of generic L-glutamine in the U.S. market.

Voxelotor's worldwide withdrawal in September 2024 also changed the branded treatment landscape. Its removal reduced the number of established disease-modifying options available to patients with persistent anemia or uncontrolled disease and increased the importance of emerging mechanisms in the clinical pipeline.

Gene Therapy Creates Revenue Disproportionate to Patient Volume

Gene therapy represented less than 0.1% of SCD treatment volume in 2025, but its contribution to market value is already significant because treatment prices are measured in millions of dollars per patient.

Casgevy carries a list price of approximately USD 2.2 million, while Lyfgenia is priced at approximately USD 3.1 million per treatment. Commercial uptake remains limited by stem-cell collection, conditioning, manufacturing, treatment-center availability, reimbursement and the clinical suitability of individual patients.

Vertex reported USD 116 million in Casgevy revenue during 2025 from 64 infusions across SCD and transfusion-dependent beta-thalassemia, while 147 patients underwent first cell collection. The company also identified more than 60,000 eligible SCD and TDT patients across approved markets, including approximately 37,000 in North America and Europe and more than 23,000 in the Middle East.

The FDA's July 2026 expansion of Casgevy to patients aged two years and older with recurrent VOCs further increased the addressable population and moved advanced therapy deeper into pediatric SCD management.

United States Concentrates High-Value Treatment Demand

The U.S. Sickle Cell Disease Drugs Market was estimated at approximately USD 440 million in 2025, representing most of North America's approximately USD 470 million market.

CDC estimates that approximately 100,000 people in the United States have SCD, with the disease occurring in around 1 in 365 Black or African American births and 1 in 16,300 Hispanic American births. Life expectancy remains more than 20 years shorter than average, while CDC continues to report gaps in recommended screening and treatment.

The U.S. represents less than 2% of the estimated global SCD population but contributes a far larger share of drug revenue because branded medicines, specialty pharmacy reimbursement and advanced therapies are used much more extensively than in many high-prevalence countries.

Gene therapy is strengthening this concentration. Vertex reported that approximately 90% of U.S. patients had reimbursed access to Casgevy by the end of 2025, supporting movement from patient referral and cell collection toward completed treatment.

North America's share is therefore driven less by disease prevalence than by treatment intensity and revenue per treated patient.

Disease Economics Support Greater Investment in Treatment

SCD produces substantial recurring healthcare expenditure. NIH-supported research has estimated average insurer-paid lifetime healthcare costs of approximately USD 1.7 million per U.S. patient, while commercially insured patients aged 64 years or younger incur approximately USD 44,000 in lifetime out-of-pocket costs.

Annual expenditure increases substantially in patients with repeated VOCs, transfusion dependence, acute chest syndrome, stroke or progressive organ damage. This creates a clinically important economic case for treatments that reduce acute-care utilization and delay cumulative complications, although high acquisition costs remain a major barrier for gene therapies.

The commercial value of future therapies will therefore increasingly depend on durable reductions in VOCs, transfusions, hospitalization and organ damage rather than short-term hematologic improvement alone.

Genotype and Disease Severity Are Increasingly Important to Market Segmentation

SCD treatment is becoming more stratified by genotype and clinical severity. Important measures include HbSS, HbSC and HbSβ-thalassemia genotype, HbF concentration, hemoglobin level, VOC frequency, acute chest syndrome history, transfusion burden, organ damage and previous hydroxyurea exposure.

Approximately 76.5% of affected births globally involve HbSS or HbSβ⁰ disease, while HbSC represents around 19.6% and HbSβ⁺ approximately 3.9%. Severe genotypes account for a disproportionate share of recurrent complications and advanced-treatment evaluation.

These populations are particularly important for pipeline development because new therapies are increasingly being assessed on annualized VOC rates, hemoglobin and HbF response, transfusion requirements, hospitalization, patient-reported pain and durable freedom from severe crises.

Treatment Penetration Will Remain the Principal Market Expansion Opportunity

The diagnosed SCD population is expected to reach approximately 6.2 million by 2032, while the disease-modifying treated population is projected to increase from approximately 1.32 million patients in 2025 to around 2.05 million. Treatment penetration among diagnosed patients would consequently rise from approximately 28% to around 33%, while still leaving most diagnosed patients outside consistent disease-modifying therapy.

Hydroxyurea is expected to remain the largest segment by treatment volume, increasing from approximately 1.18 million users in 2025 to around 1.65 million by 2032. Its revenue share, however, is expected to decline as gene therapies, newer branded treatments and pipeline products capture greater expenditure.

Gene therapies could generate approximately USD 750–850 million annually by 2032, while next-generation disease-modifying drugs could contribute another USD 450–550 million if late-stage programs translate into regulatory approvals and meaningful treatment uptake.

The resulting market remains clinically broad but commercially concentrated: inexpensive chronic therapy will continue to account for most treated patients, while a comparatively small population receiving newer branded or advanced therapies will generate an increasing share of market revenue.

Large Diagnosis and Treatment Gaps Keep the Market Underpenetrated

The central unmet need in SCD is no longer the absence of available treatment alone. It is the inability to consistently move patients from diagnosis into durable, effective disease-modifying care.

Approximately 515,000 children continue to be born with SCD each year, while millions of patients remain either unidentified, inadequately monitored or untreated. In high-burden regions, newborn screening, hydroxyurea access and specialist capacity remain priorities. In the U.S. and other developed markets, the unmet need increasingly shifts toward recurrent VOCs despite therapy, adherence, organ protection, advanced-therapy eligibility and access to curative treatment.

This divergence explains why the market can grow substantially even without rapid growth in underlying prevalence. The expansion is concentrated in diagnosed patients moving into treatment, inadequately controlled patients moving toward higher-value therapies, and a gradually increasing number of severe patients receiving advanced treatments.